News | February 28, 2026
Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Alopecia areata usually presents as a few small bald patches in the head
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Subscribe To Our Newsletter & Stay Updated
